Results 71 to 80 of about 11,024,988 (313)
PSCA CAR Vδ1 T cells: a safer off-the-shelf CAR T therapy for pancreatic cancer?
Journal for ImmunoTherapy of CancerPancreatic cancer remains among the deadliest malignancies, with a 5-year survival of ~13%. Chimeric antigen receptor (CAR) T -cell therapy offers hope, but conventional αβ T cells can trigger severe toxicities, including graft-versus-host disease (GvHD)
Jason J Lohmueller
doaj +1 more source
Acuerdo No. 40 del 18 de diciembre de 2018
, 2018 Por medio del cual se establece la meta global de carga contaminante de DBO5 y SST para la cuenca del río Seco y otros afluentes al Magdalena, para el periodo comprendido entre el 1 de enero de 2018 y el 31 de diciembre de ...
Corporación Autónoma Regional de Cundinamarca – CAR
core
FEBS Open Bio, EarlyView.This protocol paper outlines methods to establish the success of a time‐resolved serial crystallographic experiment, by means of statistical analysis of timepoint data in reciprocal space and models in real space. We show how to amplify the signal from excited states to visualise structural changes in successful experiments.
Jake Hill +4 more
wiley +1 more source
, 2018 Esta guía que se soporta en los lineamientos y referentes nacionales como los publicados por el Ministerio de Ambiente y Desarrollo Sostenible (MADS), busca aportar el paso a paso en los aspectos metodológicos a considerar para la inclusión del cambio ...
Corporación Autónoma Regional de Cundinamarca. Dirección de Gestión del Ordenamiento Ambiental y Territorial
core
FEBS Open Bio, EarlyView.Time‐restricted feeding (TRF) in mice increased liver fatty acid oxidation and decreased fatty acid biosynthesis. These alterations persisted when TRF was discontinued and the host was infected with Mycobacterium tuberculosis. Pre‐exposure to TRF did not alter tissue (lung and spleen) mycobacterial burden but significantly reduced CD3+ T cells in lungs
Ashish Gupta +7 more
wiley +1 more source
Overcoming antigen loss in CAR T therapy with Vγ9Vδ2 CAR T-cells
Immuno-Oncology and TechnologyVγ9Vδ2 T-cells demonstrate potent antitumor activity in vitro but, despite successful safety studies, the clinical benefit of Vγ9Vδ2 in adoptive cell therapy has been limited. One approach to enhance the therapeutic potential of Vγ9Vδ2 T-cells while maintaining their safety profile is genetic engineering to express a chimeric antigen receptor (CAR ...
M. Velasco Santiago +6 more
openaire +3 more sources
Acciones de la CAR con relación al río Bogotá: Políticas
, 1984 Documento que recoge las políticas diseñadas e implementadas por la CAR para la protección del Río Bogotá y cada uno de sus afluentes, en función de usos principales: Acueducto, riego y generación de energía, al igual describe la planeación para la ...
Corporación Autónoma Regional de Cundinamarca – CAR
core
, 2022 Diplomadolgozatomban különböző stimulálási és kulturálási protokollok mentén előállított harmadik generációs HER2-CAR T sejtek in vitro tumorellenes hatékonyságát vizsgálom.
Szilágyi, Ádám
core
Small RNA pathways in mammalian oocytes
FEBS Open Bio, EarlyView.Three distinct small RNA pathways operate in mammalian oocytes: RNAi interference (RNAi), the microRNA (miRNA) pathway, and the PIWI‐associated RNA (piRNA) pathway. These pathways use small RNAs to guide sequence‐specific repression and contribute to oocyte biology by targeting genes and mobile elements or appear insignificant since different ...
Petr Svoboda, Josef Pasulka
wiley +1 more source
Safe CAR-T: shedding light on CAR-related T-cell malignancies
EMBO Molecular MedicineAs of September 30, 2023, the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database has received 12 reports of secondary T-cell malignancies since the first of the BCMA-/CD19-targeted autologous CAR-T therapies was approved ...
Qibin Liao, Jianqing Xu
doaj +1 more source